Apriori Bio and A*STAR Infectious Diseases Labs Announce Strategic Partnership to Advance Next Generation Influenza Vaccines

Written by

in

CAMBRIDGE, Mass. and SINGAPORE, Nov. 18, 2025 /PRNewswire/ — Apriori Bio, a Flagship Pioneering company focused on developing prospective, variant-resilient vaccines, and the Agency for Science, Technology and Research Infectious Diseases…

Continue Reading

More posts

Asus Ramps Up ROG Xbox Ally X Production to Help Meet Demand – PCMag

November 18, 2025
From the bench to the reactor: engineered filamentous fungi for biochemical and biomaterial production | Biotechnology for Biofuels and Bioproducts

November 18, 2025
Cross-reactivity IgG, viral load, severity and vaccination outcome as an approach for understanding humoral immune response against SARS-CoV-2 | BMC Infectious Diseases

November 18, 2025
Access Denied

November 18, 2025